US stock · Healthcare sector · Medical Devices
Company Logo

Glaukos Corporation

GKOSNYSE

39.34

USD
+0.31
(+0.79%)
Market Closed
-66.71P/E
-30Forward P/E
-2.57P/E to S&P500
1.862BMarket CAP
- -Div Yield
Upcoming Earnings
3 Aug-8 Aug
Shares Short
4/29/22
1.98M
Short % of Float
7.11%
Short % of Shares Outs.
4.19%
% Held by Insiders
3.88%
% Held by Institutions
93.40%
Beta
1.48
PEG Ratio
-2.79
52w. high/low
87.24/33.33
Avg. Daily Volume
0.49M
Return %
Stock
S&P 500
1 year
(48.15)
(6.45)
3 years
(41.34)
36.49
5 years
6.09
63.16
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
33.92
18.53
39.82
14.25
52.49
23.07
70.91
25.25
84.65
50.60
76.20
23.31
99.00
39.35
64.49
33.33
Currency: USD
- -
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
0.84
1.91
4.10
3.47
4.63
5.13
6.34
5.06
6.29
6.28
Earnings per share
- -
- -
- -
- -
- -
- -
- -
(0.51)
(0.51)
(2.13)
0.14
(0.00)
(0.37)
0.41
(2.70)
(1.06)
(0.61)
FCF per share
- -
- -
- -
- -
- -
- -
- -
(0.57)
(0.33)
(0.18)
0.18
0.56
0.24
(0.14)
(0.67)
(0.49)
(0.15)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
0.03
0.04
0.05
0.19
0.18
0.29
0.13
0.16
1.02
0.80
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
0.60
0.25
5.45
3.56
4.02
4.92
18.02
15.00
12.56
12.67
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
25
24
17
33
34
35
37
44
47
47
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
(12.6)
193.5
(14,440.0)
(122.1)
164.3
(17.9)
(65.0)
(66.7)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.6)
8.7
(612.1)
(4.9)
6.8
(0.5)
(2.2)
(2.6)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
21
46
72
114
159
181
237
225
294
294
Operating margin
- -
- -
- -
- -
- -
- -
- -
(67.8)%
(28.9)%
(14.4)%
3.7%
(1.4)%
(7.2)%
(21.2)%
(54.9)%
(11.2)%
(3.3)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
1
4
4
5
5
6
10
35
34
35
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
(13)
(12)
(37)
5
(0)
(13)
15
(120)
(50)
(28)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
(0.0)%
(0.1)%
(0.1)%
0.9%
9,300.0%
(4.7)%
130.8%
9.0%
(0.7)%
2.3%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
(60.3)%
(26.6)%
(51.9)%
4.0%
(0.1)%
(7.1)%
6.5%
(53.5)%
(16.9)%
(9.0)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
6
(10)
84
103
123
146
205
420
423
436
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
18
9
1
- -
- -
- -
73
271
382
382
Equity (m)
- -
- -
- -
- -
- -
- -
- -
15
6
95
117
138
174
673
667
587
598
ROIC
- -
- -
- -
- -
- -
- -
- -
(37.2)%
(72.8)%
(37.6)%
4.4%
(3.0)%
(7.3)%
1.9%
(11.2)%
(3.7)%
(1.4)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
(31.9)%
(31.5)%
(31.0)%
3.8%
0.0%
(6.0)%
(5.8)%
(11.8)%
(3.4)%
(1.3)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
(84.8)%
(199.4)%
(39.1)%
3.9%
(0.1)%
(7.4)%
2.3%
(18.0)%
(8.4)%
(4.6)%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
5 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 455
Total assets
$ 1,052
Long-term debt
$ 382
Cash and equiv.
$ 106
Goodwill
$ 66
Retained earnings
$ (360)
Common stock
47
Enterprise Value
$ 2,138
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
174
404
414
Receivables
38
36
33
Inventory
43
16
23
Other
8
47
54
Current assets
263
469
486
Acc. Payable
6
4
7
Debt due
- -
- -
- -
Other
52
45
56
Current liabilities
58
50
63
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
30.70%
17.55%
- -
Cash flow
(22.88)%
62.40%
- -
Earnings
(58.79)%
3,204.76%
- -
Dividends
- -
- -
- -
Book value
(12.03)%
75.04%
- -
Insider Trading
Type
Shares
Date
Kliman Gilbert H
Other
980
05/18/22
Kliman Gilbert H
Other
980
05/18/22
Navratil Tomas
InKind
338
04/19/22
Gilliam Joseph E
InKind
672
04/19/22
Burns Thomas William
InKind
3,823
04/19/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
55
32
65
73
225
2021
68
78
75
73
294
2022
68
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(1.21)
(0.90)
(0.35)
(0.24)
(2.70)
2021
(0.35)
(0.37)
0.13
(0.47)
(1.06)
2022
0.11
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Thomas Burns
Full-time employees:
727
City:
San Clemente
Address:
229 Avenida Fabricante
IPO:
Jun 25, 2015
Website:
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.